Viscoelastic pharmacodynamics after dalteparin administration to healthy dogs

Abstract

Viscoelastic coagulation monitoring with strong coagulation activators may be used to monitor treatment with dalteparin in healthy dogs.

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

“…Various publications have determined pharmacokinetics of low‐molecular‐weight heparins in dogs . Considerable variation in anti‐Xa activities has been documented and some uncertainty remains about the efficacy of enoxaparin in some breeds of dog .…”

“…, but this study was underpowered and does not demonstrate equivalency of interventions 27. Various publications have determined pharmacokinetics of lowmolecular-weight heparins in dogs [150][151][152]. Considerable variation in anti-Xa activities has been documented and some uncertainty remains about the efficacy of enoxaparin in some breeds of dog 55,152,153.…”

Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs

“…Hemostatic tests such as prothrombin time (PT), partial thromboplastin time (PTT), and platelet function tests are not sensitive enough to detect hypercoagulable states in human and veterinary patients . In recent years, viscoelastic testing methods such as thromboelastography (TEG) and thromboelastometry (TEM) have been increasingly used to identify hyper‐ and hypocoagulable states in dogs . However, viscoelastic testing results may not reflect in vivo hemostasis of a patient in all situations.…”

Postoperative Hemostasis Monitoring and Management

“…In veterinary medicine, the pharmacokinetics are less favorable, and LMWHs likely require at least 3-times-a-day dose administration to maintain anticoagulant effect in dogs and cats. 76,77 The timing of initiation and duration of anticoagulant therapy after surgery remains controversial in people, as the risk of postoperative VTE varies based on the procedure and the patient. The greatest risk of bleeding from anticoagulant therapy is 12 hours before or after surgery, and current human recommendations for LMWH therapy initiate therapy 12 hours after surgery and continue up to 35 days.…”